Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Net loss $ (49,315) $ (51,419)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 49,518 51,281
Non-cash interest 2,198 1,294
Amortization of deferred financing costs 99 112
Losses from investments in investees 9,669 7,758
Equity-based compensation – employees and non-employees 11,514 15,844
Gain on disposal of fixed assets (495) (2,473)
Change in fair value of equity securities and derivative instruments (14,819) (9,519)
Change in fair value of contingent consideration (13,599) 6,738
Deferred income tax benefit (2,026) (23,039)
Changes in assets and liabilities, net of the effects of acquisitions:    
Accounts receivable, net 12,440 (30,865)
Inventory, net 894 (443)
Other current assets and prepaid expenses (3,730) 3,692
Other assets (146) (254)
Accounts payable (8,092) 9,439
Foreign currency measurement (77) 230
Contract liabilities (30,812) (31,122)
Accrued expenses and other liabilities (15,820) (3,837)
Net cash used in operating activities (52,599) (56,583)
Cash flows from investing activities:    
Investments in investees (1,000) (3,000)
Proceeds from sale of equity securities 1,286 0
Purchase of marketable securities 0 (5)
Proceeds from the sale of property, plant and equipment 840 3,398
Capital expenditures (12,792) (16,805)
Net cash used in investing activities (11,666) (16,412)
Cash flows from financing activities:    
Issuance of 2033 Senior Notes, including to related parties 55,000 0
Proceeds from the exercise of Common Stock options and warrants 318 1,916
Borrowings on lines of credit 18,817 45,524
Repayments of lines of credit (20,924) (13,525)
Net cash provided by financing activities 53,211 33,915
Effect of exchange rate changes on cash and cash equivalents (64) 877
Net decrease in cash and cash equivalents (11,118) (38,203)
Cash and cash equivalents at beginning of period 91,499 168,733
Cash and cash equivalents at end of period 80,381 130,530
SUPPLEMENTAL INFORMATION:    
Interest paid 785 748
Income taxes paid, net of refunds 5,251 4,321
Shares issued upon the conversion of:    
Common Stock options and warrants, surrendered in net exercise 806 1,546
OPKO Health Europe    
Issuance of capital stock for contingent consideration settlement:    
OPKO Health Europe $ 0 $ 303